Results 161 to 170 of about 2,835 (182)

Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies

British Journal of Clinical Pharmacology, 2022
Cara Nelson, Amy Meng
exaly  

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial

Rheumatology, 2022
Robert Landewé, Walter P Maksymowych, Robin Besuyen   +2 more
exaly  

Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects

Clinical Pharmacology in Drug Development, 2020
Florence Namour
exaly  

Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2)

Modern Rheumatology, 2022
Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara   +2 more
exaly  

Filgotinib Induces and Maintains Ulcerative Colitis Remission

JAMA, 2021
openaire   +2 more sources

The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects

Clinical Pharmacology in Drug Development, 2019
Florence Namour, Shringi Sharma
exaly  

Validated LC–MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats

Biomedical Chromatography, 2020
Ramesh Mullangi
exaly  

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Lancet, The, 2017
Séverine Vermeire, Xavier Hebuterne, Xavier Roblin   +2 more
exaly  

Baricitinib/Filgotinib

Reactions Weekly
openaire   +1 more source

Rheumatoide Arthritis: Filgotinib mit gutem Sicherheitsprofil

Orthopädie & Rheuma, 2021
openaire   +1 more source